CDMO Add to watchlist $12.49 +0.00 (+0.00%) Last updated: Jul 16, 2026 00:05
52-Week Range
$12.49
$9.99 $12.49 $14.99

Fundamentals Overview

Avid Bioservices, Inc. is in the middle of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/B 12.96 P/S 5.71

Intrinsic value (DCF)

+0% upside vs price

Risk (Beta)

1.41 — higher vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 44% confidence Risk: High Volatility — Beta 1.41. Consider smaller position size due to higher beta.

Pressures (Sell):

Beta 1.41 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$798.90M
P/E (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
N/A
52-Week Range
$9.99 - $14.99
Volume vs Avg
N/A
Beta
1.41

About

Avid Bioservices, Inc. operates as a Contract Development and Manufacturing Organization (CDMO), specializing in the development and CGMP-compliant production of biopharmaceutical drug substances. Their core expertise lies in compounds derived from mammalian cell culture, providing both clinical and commercial scale manufacturing solutions. The company is proficient in producing critical therapeutics such as monoclonal antibodies and recombinant proteins. Beyond manufacturing, their comprehensiv...
Sector: Healthcare
Headquarters: US
Employees: 371
IPO Date: Apr 1994
Beta: 1.41 (More volatile than market)

Ratings & Grades at a Glance

Recent institutional grades: mixed. Current institutional positions: Buy: 3, Outperform: 14, Overweight: 11, Sector Perform: 1, Sector Weight: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $12.49; current price is $12.49. That’s a +0% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) N/A
DCF value (model) $12.49 (0% vs price)
PEG (TTM) N/A
P/B (TTM) 12.96
P/S (TTM) 5.71
Liquidity & enterprise
Current Ratio (TTM) 1.47
Quick Ratio (TTM) 1.04
Cash Ratio (TTM) 0.54
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) -1.01%
Gross margin (TTM) 5.23%
Operating margin (TTM) -13.35%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for CDMO.

Analyst Sentiment at a Glance

Sentiment Mixed
Buy 3Outperform 14Overweight 11Sector Perform 1Sector Weight 1
2 upgrades, 2 downgrades
Consensus Target
$8.00
High Target
$8.00
Low Target
$8.00
Median Target
$8.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
RBC Capital downgrade Outperform Sector Perform 2024-11-07
RBC Capital maintain Outperform Outperform 2024-09-10
Stephens & Co. maintain Overweight Overweight 2024-09-10
RBC Capital maintain Outperform Outperform 2024-07-03
RBC Capital maintain Outperform Outperform 2024-04-30
Stephens & Co. maintain Overweight Overweight 2024-03-11
RBC Capital maintain Outperform Outperform 2024-03-07
Craig-Hallum maintain Buy Buy 2023-12-08
Keybanc maintain Overweight Overweight 2023-12-08
RBC Capital maintain Outperform Outperform 2023-12-08
RBC Capital maintain Outperform Outperform 2023-09-08
RBC Capital maintain Outperform Outperform 2023-09-07
Stephens & Co. maintain Overweight Overweight 2023-06-22
RBC Capital maintain Outperform Outperform 2023-06-22
Stephens& Co. maintain Overweight Overweight 2023-06-22
RBC Capital maintain Outperform Outperform 2023-06-21
Stephens & Co. maintain Overweight Overweight 2023-06-21
Stephens& Co. maintain Overweight Overweight 2023-06-21
Keybanc upgrade Sector Weight Overweight 2023-03-14
Keybanc upgrade Sector Weight Overweight 2023-03-13
RBC Capital maintain Outperform Outperform 2022-12-07
RBC Capital maintain Outperform Outperform 2022-12-06
RBC Capital maintain Outperform Outperform 2022-06-30
RBC Capital maintain Outperform Outperform 2022-06-29
Stephens & Co. maintain Overweight Overweight 2022-03-09
Stephens & Co. maintain Overweight Overweight 2022-03-08
Craig-Hallum maintain Buy Buy 2021-12-08
RBC Capital maintain Outperform Outperform 2021-12-08
Keybanc downgrade Overweight Sector Weight 2021-12-08
Craig-Hallum maintain Buy Buy 2021-12-07